Literature DB >> 7840557

Longitudinal study of susceptibilities of species of the Bacteroides fragilis group to five antimicrobial agents in three medical centers.

P Turgeon1, V Turgeon, M Gourdeau, J Dubois, F Lamothe.   

Abstract

A total of 579 clinical isolates of the Bacteroides fragilis group collected from three Canadian hospitals were tested for susceptibility to five antimicrobial agents by using an agar dilution method. During the 4-year survey, isolates from intra-abdominal infections were collected from the following sites: abdominal abscesses (48%), peritoneal fluid (39%), blood (10%), and bile (3%). B. fragilis was the most prevalent species (35.4%), followed by B. thetaiotaomicron (19.2%), B. ovatus (15.9%), and B. vulgatus (11%). No metronidazole- or imipenem-resistant strains were found during the survey. Resistance profiles varied among the different species tested: 7.8, 2.9, and 7.3% of B. fragilis strains (n = 205) and 68.1, 17.2, and 9.4% of non-B. fragilis strains (n = 373) were resistant to cefotetan, cefoxitin, and clindamycin, respectively. B. fragilis and B. vulgatus demonstrated lower resistance rates than B. thetaiotaomicron, B. ovatus, B. distasonis, and B. caccae. During the study, rates of resistance to cefotetan and clindamycin fluctuated but rates of resistance to cefoxitin increased, particularly at one center. These data indicate a need to determine the susceptibility patterns of the B. fragilis group periodically at each hospital.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7840557      PMCID: PMC284730          DOI: 10.1128/AAC.38.10.2276

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Comparative activities of newer beta-lactam agents against members of the Bacteroides fragilis group.

Authors:  G J Cuchural; F P Tally; N V Jacobus; T Cleary; S M Finegold; G Hill; P Iannini; J P O'Keefe; C Pierson
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

2.  Susceptibility to five antimicrobial agents of strains of the Bacteroides fragilis group isolated in Brazil.

Authors:  A E De Almeida; M De Uzeda
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

Review 3.  Antimicrobial resistance in Bacteroides.

Authors:  H M Wexler; S M Finegold
Journal:  J Antimicrob Chemother       Date:  1987-02       Impact factor: 5.790

4.  Survey of anaerobic susceptibility patterns in Canada.

Authors:  A M Bourgault; G K Harding; J A Smith; G B Horsman; T J Marrie; F Lamothe
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

5.  Nationwide study of the susceptibility of the Bacteroides fragilis group in the United States.

Authors:  F P Tally; G J Cuchural; N V Jacobus; S L Gorbach; K Aldridge; T Cleary; S M Finegold; G Hill; P Iannini; J P O'Keefe
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

6.  Bacteroides fragilis: current susceptibilities, mechanisms of drug resistance, and principles of antimicrobial therapy.

Authors:  G J Cuchural; F P Tally
Journal:  Drug Intell Clin Pharm       Date:  1986 Jul-Aug

7.  Activity of newer beta-lactam agents against clinical isolates of Bacteroides fragilis and other Bacteroides species.

Authors:  J P O'Keefe; F R Venezio; C A DiVincenzo; K L Shatzer
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

8.  Annual incidence, epidemiology, and comparative in vitro susceptibilities to cefoxitin, cefotetan, cefmetazole, and ceftizoxime of recent community-acquired isolates of the Bacteroides fragilis group.

Authors:  E J Goldstein; D M Citron
Journal:  J Clin Microbiol       Date:  1988-11       Impact factor: 5.948

9.  Antimicrobial susceptibility patterns and resistance transferability among Bacteroides fragilis group isolates from patients with appendicitis in Bali, Indonesia.

Authors:  K Suata; K Watanabe; K Ueno; M Homma
Journal:  Clin Infect Dis       Date:  1993-04       Impact factor: 9.079

10.  Susceptibility of the Bacteroides fragilis group in the United States: analysis by site of isolation.

Authors:  G J Cuchural; F P Tally; N V Jacobus; K Aldridge; T Cleary; S M Finegold; G Hill; P Iannini; J P O'Keefe; C Pierson
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

View more
  6 in total

1.  Trends in antimicrobial resistance among clinical isolates of the Bacteroides fragilis group from 1992 to 1997 in Montreal, Canada.

Authors:  A C Labbé; A M Bourgault; J Vincelette; P L Turgeon; F Lamothe
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

Review 2.  Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections.

Authors:  J A Balfour; H M Bryson; R N Brogden
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

3.  In vitro activities of MK-0826 and 16 other antimicrobials against Bacteroides fragilis group strains.

Authors:  C Betriu; A Sánchez; M L Palau; M Gómez; J J Picazo
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

4.  Bacteroides fragilis group: trends in resistance.

Authors:  Manfred Fille; Monica Mango; Matthias Lechner; Reiner Schaumann
Journal:  Curr Microbiol       Date:  2006-01-31       Impact factor: 2.188

5.  Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group: comparison with the activities of 14 other agents.

Authors:  C Betriu; M Gómez; M L Palau; A Sánchez; J J Picazo
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

6.  Impact of anatomic site on growth, efflux-pump expression, cell structure, and stress responsiveness of Bacteroides fragilis.

Authors:  Lilian Pumbwe; Christopher A Skilbeck; Hannah M Wexler
Journal:  Curr Microbiol       Date:  2007-07-26       Impact factor: 2.188

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.